-
The Synthetic Routes of IMatinib Para-diaMinoMethylbenzene
Time of Update: 2023-04-25
Another synthetic route that can be used to prepare IMatinib Para-diaMinoMethylbenzene involves the use of a phosphine-mediated coupling reaction.
Another synthetic route that can be used to prepare IMatinib Para-diaMinoMethylbenzene involves the use of a phosphine-mediated coupling reaction.
-
The Instruction of IMatinib Para-diaMinoMethylbenzene
Time of Update: 2023-04-25
In conclusion, the synthesis, purification, and characterization of imatinib para-dimethylaminobenzene are essential steps in the development of this promising pharmaceutical drug.
In conclusion, the synthesis, purification, and characterization of imatinib para-dimethylaminobenzene are essential steps in the development of this promising pharmaceutical drug.
-
The Production Process of IMatinib Para-diaMinoMethylbenzene
Time of Update: 2023-04-25
Additionally, the process produces PDMB that is highly pure, which is essential for its use in the production of a range of specialty chemicals.
Additionally, the process produces PDMB that is highly pure, which is essential for its use in the production of a range of specialty chemicals.
-
A clinical predictive model for first-line imatinib treatment failure in chronic myeloid leukemia
Time of Update: 2023-01-04
Recently, the team of Professor Jiang Qian & Huang Xiaojun of the Institute of Hematology of Peking University published a clinical prediction model on the failure of chronic myeloid leukemia to receive imatinib.
-
such as imatinib can improve metabolic complications induced by new coronavirus infection
Time of Update: 2022-03-08
On February 11, 2022, Sun Yat-Sen University, Chen Sifan, Yan Li, Deng Kai and Li Zilun, published a joint communication online in Cell Metabolism entitled "Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry" , which showed that impairment of the ACE2 pathway is a key factor linking viral infection to its secondary metabolic sequelae .
-
Clin Cancer Res: Efficacy of adjuvant imatinib therapy in GIST patients with KIT exon 9 mutations: a European multicenter retrospective study
Time of Update: 2021-10-20
This retrospective study showed that GIST patients with KIT exon 9 mutations received adjuvant imatinib treatment, and a daily dose of 800 mg did not have a better survival prognosis than 400 mg a day .
-
Lancet Diabetes Endocrinol: The efficacy of imatinib in the treatment of patients with newly-onset type 1 diabetes
Time of Update: 2021-10-19
The primary endpoint was the difference in the average area under the curve (AUC) of the C-peptide response 2 hours before the MMTT between the imatinib group and the placebo group at 12 months.
-
Only 27 million imatinib was sold
Time of Update: 2021-08-30
Shanghai Modern Pharmaceutical stated that after the signing of this contract, Sinopharm Yixin still needs to complete the change of the relevant preparation marketing license holder, and will implement the transfer of raw material technology and the change of preparation production address.
-
Preserving β-cell function Imatinib has the potential to change the course of type 1 diabetes
Time of Update: 2021-08-06
At 12 months, patients in the imatinib treatment group had better retention of insulin secretion, and the area under the curve (AUC) of the C-peptide response 2 hours before MMTT was higher.
-
Sinopharm Hyundai: Obtained the rights and interests of imatinib mesylate and its preparations
Time of Update: 2021-07-06
On June 21, Sinopharm Hyundai announced that its holding subsidiary Sinopharm Yixin and Xinlitai signed the "Technology Transfer Contract", and Xinlitai transferred its imatinib mesylate raw materials and related rights and interests in its preparations to Sinopharm Yixin .
-
Qilu imatinib mesylate tablets will be approved soon
Time of Update: 2021-06-11
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with imatinib mesylate tablets reported for production in category 4 imitations.
At present, CSPC Ouyi, Hausen, and Novartis have approved the production of imatinib mesylate tablets in China.
-
University of Dundee, UK: Kinase drug discovery after 20 years of imatinib: progress and future directions
Time of Update: 2021-06-01
Here, the author reviews the remarkable progress made in improving the potency and specificity of small molecule inhibitors of protein and lipid kinases over the past 20 years, leading to the approval of more than 70 new drugs since the approval of imatinib in 2001 .
-
"Mr. Critical" for Imatinib resistance has been found
Time of Update: 2021-04-22
Therefore, from the perspective of functional genomics, Wang Yuexiang’s research team proved for the first time that CDK1 is the offensive weakness of imatinib-resistant gastrointestinal stromal tumors, and clarified the new functions and substrates of CDK1 outside the cell cycle, and proposed CDK1 drive The treatment strategy of gastrointestinal stromal tumors provides new strategies and preclinical experimental data for overcoming imatinib resistance.
-
Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report
Time of Update: 2021-03-07
Detection of mutations is helpful in clinical management of imatinib resistance.
We established a very sensitive (ASO)PCR to detect mutations in an imatinib-resistant CML patient.
Moreover, this ASO-PCR assay is very effective in detecting mutations related to imatinib resistance.
-
ASCO 2020: MEK162 (Bemetinib) Joint Imatinib Treatment of Advanced Gastrointestinal Interside Tumor phase II Clinical Study
Time of Update: 2020-05-29
BACKGROUND: ETV1 and KIT are the main transcription factors and signal survival factors of the family of gastrointestinal mesothelioma In the preclinical model, BINI inhibited ETV1 and Imatinib inh